Intuitive Fosun Medical Device Technology (Shanghai) Co., Ltd.
In 2017, Fosun Pharma and US Insight Medical, a global leader in medical surgical robots, formed a joint venture in China Insight Fosun. Since its establishment, Fosun has always adhered to the core values of "patient first" and adhered to the purpose of "Made in China, joint research and development, and global sales". The company's star products, Da Vinci surgical system and Ion bronchoscopic operation control system (not available in China), have been widely recognized and used around the world as revolutionary products that guide the development of minimally invasive surgery. By empowering Chinese medical institutions and doctors, we will then allow cutting-edge minimally invasive surgical technology to benefit Chinese patients, and contribute to the innovation and development of China's medical industry with the determination of openness, inclusiveness, inclusiveness, balance and win-win. The company firmly believes that minimally invasive diagnosis and treatment technology is designed to improve the quality of life; it integrates originality and intelligent technology to provide unlimited possibilities for doctors and patients. Intuitive Fosun has always been concerned about the development trend of China's medical and health industry. With the purpose of "Made in China, joint research and development, global sales", it has deepened its roots in China and served China, and continuously introduced high-quality and effective innovative medical technologies and products to meet medical personnel and Patient needs. In July 2022, the medical robot manufacturing and R&D center of the intuitive Fosun headquarters and industrialization base project officially started construction. This is another major strategic layout after the completion of the Da Vinci Innovation Center in 2021. It marks the integration of multiple locations into a large park including production and manufacturing and innovation centers, and it is also the deepening of localization of Fosun. Another important milestone in the strategic layout.
Intuitive Fosun Medical Device Technology (Shanghai) Co., Ltd.
In 2017, Fosun Pharma and US Insight Medical, a global leader in medical surgical robots, formed a joint venture in China Insight Fosun. Since its establishment, Fosun has always adhered to the core values of "patient first" and adhered to the purpose of "Made in China, joint research and development, and global sales". The company's star products, Da Vinci surgical system and Ion bronchoscopic operation control system (not available in China), have been widely recognized and used around the world as revolutionary products that guide the development of minimally invasive surgery. By empowering Chinese medical institutions and doctors, we will then allow cutting-edge minimally invasive surgical technology to benefit Chinese patients, and contribute to the innovation and development of China's medical industry with the determination of openness, inclusiveness, inclusiveness, balance and win-win. The company firmly believes that minimally invasive diagnosis and treatment technology is designed to improve the quality of life; it integrates originality and intelligent technology to provide unlimited possibilities for doctors and patients. Intuitive Fosun has always been concerned about the development trend of China's medical and health industry. With the purpose of "Made in China, joint research and development, global sales", it has deepened its roots in China and served China, and continuously introduced high-quality and effective innovative medical technologies and products to meet medical personnel and Patient needs. In July 2022, the medical robot manufacturing and R&D center of the intuitive Fosun headquarters and industrialization base project officially started construction. This is another major strategic layout after the completion of the Da Vinci Innovation Center in 2021. It marks the integration of multiple locations into a large park including production and manufacturing and innovation centers, and it is also the deepening of localization of Fosun. Another important milestone in the strategic layout.
Stryker (Beijing) Medical Devices Co., Ltd.
As one of the world's cutting-edge medical technology companies, Stryker works sincerely with customers and is committed to improving healthcare. The company provides a range of innovative products and services including plastic surgery, medical and surgical equipment, neurosurgery and spine-related products to help improve the treatment experience of patients and medical institutions. Dr. Homer Stryker, an orthopedic physician in Kalamazoo, Michigan, invented a series of new products after discovering that some medical products cannot meet the needs of patients. There is growing concern and interest in these new medical products, and Dr. Stryker founded The Orthopaedic Frame Company in 1941, specializing in the production of these innovative medical products. In 1942, the company began to build wedge-shaped turnover beds, which allow caregivers to turn over patients with severe back injuries while keeping their spine fixed; In 1946, Stryker founded The Orthopaedic Frame Company; In 1979, the company issued its shares for the first time, bringing more attention to the company; in the same year, Stryker acquired Osteonics Corp. and entered the orthopedic implant market; In 1981, the company's acquisition of SynOptics provided an opportunity to expand into its endoscope business; In 1992, the acquisition of Dimso, SA opened up business opportunities in the field of spinal fixation; In 1996, the acquisition of Osteo SA provided an opportunity to enter the bone trauma market; In 1997, 18 years after the company was listed on the Nasdaq, the company was listed on the New York Stock Exchange; In 1998, the company acquired Howmedica, a major player in the orthopedic market, and doubled its size in the coming year. In 2009, the company acquired Ascent Healthcare Solutions, Inc., a leading market leader in the U.S. medical device reprocessing and remanufacturing market; In 2011, the company acquired Boston Scientific's neurovascular division, greatly expanding the brand's neurotechnology business; In 2013, the company acquired Trauson Holdings Company Limited to expand into high-value market segments in emerging markets. In the same year, the company's acquisition of MAKO Surgical Corp provided an opportunity to further promote the development of robotic arm-assisted surgery in orthopedics.
Stryker (Beijing) Medical Devices Co., Ltd.
As one of the world's cutting-edge medical technology companies, Stryker works sincerely with customers and is committed to improving healthcare. The company provides a range of innovative products and services including plastic surgery, medical and surgical equipment, neurosurgery and spine-related products to help improve the treatment experience of patients and medical institutions. Dr. Homer Stryker, an orthopedic physician in Kalamazoo, Michigan, invented a series of new products after discovering that some medical products cannot meet the needs of patients. There is growing concern and interest in these new medical products, and Dr. Stryker founded The Orthopaedic Frame Company in 1941, specializing in the production of these innovative medical products. In 1942, the company began to build wedge-shaped turnover beds, which allow caregivers to turn over patients with severe back injuries while keeping their spine fixed; In 1946, Stryker founded The Orthopaedic Frame Company; In 1979, the company issued its shares for the first time, bringing more attention to the company; in the same year, Stryker acquired Osteonics Corp. and entered the orthopedic implant market; In 1981, the company's acquisition of SynOptics provided an opportunity to expand into its endoscope business; In 1992, the acquisition of Dimso, SA opened up business opportunities in the field of spinal fixation; In 1996, the acquisition of Osteo SA provided an opportunity to enter the bone trauma market; In 1997, 18 years after the company was listed on the Nasdaq, the company was listed on the New York Stock Exchange; In 1998, the company acquired Howmedica, a major player in the orthopedic market, and doubled its size in the coming year. In 2009, the company acquired Ascent Healthcare Solutions, Inc., a leading market leader in the U.S. medical device reprocessing and remanufacturing market; In 2011, the company acquired Boston Scientific's neurovascular division, greatly expanding the brand's neurotechnology business; In 2013, the company acquired Trauson Holdings Company Limited to expand into high-value market segments in emerging markets. In the same year, the company's acquisition of MAKO Surgical Corp provided an opportunity to further promote the development of robotic arm-assisted surgery in orthopedics.
Medtronic (Shanghai) Management Co., Ltd.
Because of extraordinary technology, life is facing severe health challenges, Medtronic uses advanced medical technology to bring extraordinary life experience to patients and inspire hope and possibilities in people's lives. Every day, many people face severe health challenges, but ordinary life is a luxury for them. When a type I diabetic patient went out to a friend's house, his father often worried about his son's blood sugar soaring; a woman with an arrhythmia was worried all day long. Some things that seem natural to ordinary people are troubled and struggled by. As a global medical technology company, Medtronic has expectations and strives to achieve more possibilities through innovation and its own profession, bringing patients an extraordinary life experience. Medtronic is committed to solving the complex challenges facing today's healthcare systems, and its business has expanded to more than 70 key disease areas. Medtronic acts quickly and seizes the day to serve more patients around the world with medical technology. Introduce data, artificial intelligence, automation technologies based on patient needs – turning insights into actions to make continuous improvements to the healthcare system. We hope to use technology to ignite the hope of life for patients and bring new possibilities. Medtronic operates in more than 150 countries and regions and has more than 90,000 employees worldwide. We expand access and strive to create more positive impacts beyond our own products. We are committed to promoting inclusion, diversity and equity, and we are committed to protecting our planet to create better results for all.
Medtronic (Shanghai) Management Co., Ltd.
Because of extraordinary technology, life is facing severe health challenges, Medtronic uses advanced medical technology to bring extraordinary life experience to patients and inspire hope and possibilities in people's lives. Every day, many people face severe health challenges, but ordinary life is a luxury for them. When a type I diabetic patient went out to a friend's house, his father often worried about his son's blood sugar soaring; a woman with an arrhythmia was worried all day long. Some things that seem natural to ordinary people are troubled and struggled by. As a global medical technology company, Medtronic has expectations and strives to achieve more possibilities through innovation and its own profession, bringing patients an extraordinary life experience. Medtronic is committed to solving the complex challenges facing today's healthcare systems, and its business has expanded to more than 70 key disease areas. Medtronic acts quickly and seizes the day to serve more patients around the world with medical technology. Introduce data, artificial intelligence, automation technologies based on patient needs – turning insights into actions to make continuous improvements to the healthcare system. We hope to use technology to ignite the hope of life for patients and bring new possibilities. Medtronic operates in more than 150 countries and regions and has more than 90,000 employees worldwide. We expand access and strive to create more positive impacts beyond our own products. We are committed to promoting inclusion, diversity and equity, and we are committed to protecting our planet to create better results for all.
Johnson & Johnson (China) Investment Co., Ltd.
Johnson & Johnson Medical Technology’s global history can be traced back to the beginning of Johnson & Johnson’s establishment in the United States in 1886. As one of the healthcare companies with wide business worldwide, Johnson & Johnson originated from the production of sterile surgical sutures and auxiliary materials. For more than a century, Johnson & Johnson Medical Technology has always been committed to becoming a world-leading medical technology innovator and bringing far-reaching significance to human health with rich and diverse professional accumulation, mission-significant scientific innovation, and high enthusiasm for human health. Influence, let people all over the world have a healthy and beautiful life. At present, in the fields of surgery, cardiovascular and professional solutions, orthopedics and ophthalmology, Johnson & Johnson Medical Technology continues to innovate and deepen its efforts around the world, striving to solve unmet medical needs, reimagine the future of human health, and allow medical solutions to Smarter, more minimally invasive, more personalized, protect life and light up every beam of hope. In 1994, Johnson & Johnson Medical Technology entered the Chinese market. Currently, Johnson & Johnson Medical Technology has more than 5,000 employees in China, of which 85% are new generation employees. It is headquartered in Shanghai and has offices in Beijing, Guangzhou and other places. On the road of growing together with China's medical and health industry, we will continue to expand and improve our product layout and supply chain production capacity in China. At present, medical technology has become Johnson & Johnson's largest business segment in China. In recent years, Johnson & Johnson Medical Technology has continued to deepen its layout of end-to-end supply chain systems in China, improve local intelligent manufacturing capabilities, introduce global advanced product, technology and quality management experience, and help the industry develop at a high quality and high speed. The integrated supply chain production base located in Suzhou Industrial Park is a large comprehensive industrial park of Johnson & Johnson Medical Technology in China. It integrates the research and development and manufacturing of medical equipment, technological innovation and cooperation, global shared services, regional procurement and supplier management. and other diversified business functions, among which the intelligent manufacturing factory produces a series of innovative products such as surgery and orthopedics, responds to local demand and supplies globally. Johnson & Johnson Medical Technology not only focuses on cultivating and upgrading local intelligent manufacturing capabilities, but also further focuses on local R&D and innovation capabilities. In addition to Suzhou Supply Chain Base, Guangzhou Beixiu Biotechnology Co., Ltd., a wholly-owned subsidiary of Johnson & Johnson, is a biotechnology company specializing in technology development, research and production of pig-derived biological products. Beixiu independently developed the technology to extract fibrinogen and thrombin from mammalian blood, which is the world's first biomedical innovation. On the road to growing together with China's medical and healthcare industry, Johnson & Johnson Medical Technology has deepened the professional education and training of Chinese professional medical staff and is committed to becoming a trustworthy partner of Chinese medical staff. In line with the purpose of "exploring human technology and caring about human health", three Johnson & Johnson Medical Technology Professional Education Academic Centers located in Beijing, Shanghai and Boao Lecheng Medical Pilot Zone and the digital doctor training and education platform "Ling Yimai" provide professional knowledge, Training to adapt to China's medical service environment and innovative medical education forms will be promoted to the professional and systematic development of continuing medical education. In addition, Johnson & Johnson Medical Technology is also actively working with partners from all walks of life to promote innovation cooperation, accelerate the transformation of innovative results, and serve patients. As part of Johnson & Johnson's China Innovation Engine Strategy, Johnson & Johnson cooperates with local companies to leverage digital technologies such as artificial intelligence, surgical robots, and big data to assist doctors in more effective perioperative work and establish localized digital surgical solutions.
Johnson & Johnson (China) Investment Co., Ltd.
Johnson & Johnson Medical Technology’s global history can be traced back to the beginning of Johnson & Johnson’s establishment in the United States in 1886. As one of the healthcare companies with wide business worldwide, Johnson & Johnson originated from the production of sterile surgical sutures and auxiliary materials. For more than a century, Johnson & Johnson Medical Technology has always been committed to becoming a world-leading medical technology innovator and bringing far-reaching significance to human health with rich and diverse professional accumulation, mission-significant scientific innovation, and high enthusiasm for human health. Influence, let people all over the world have a healthy and beautiful life. At present, in the fields of surgery, cardiovascular and professional solutions, orthopedics and ophthalmology, Johnson & Johnson Medical Technology continues to innovate and deepen its efforts around the world, striving to solve unmet medical needs, reimagine the future of human health, and allow medical solutions to Smarter, more minimally invasive, more personalized, protect life and light up every beam of hope. In 1994, Johnson & Johnson Medical Technology entered the Chinese market. Currently, Johnson & Johnson Medical Technology has more than 5,000 employees in China, of which 85% are new generation employees. It is headquartered in Shanghai and has offices in Beijing, Guangzhou and other places. On the road of growing together with China's medical and health industry, we will continue to expand and improve our product layout and supply chain production capacity in China. At present, medical technology has become Johnson & Johnson's largest business segment in China. In recent years, Johnson & Johnson Medical Technology has continued to deepen its layout of end-to-end supply chain systems in China, improve local intelligent manufacturing capabilities, introduce global advanced product, technology and quality management experience, and help the industry develop at a high quality and high speed. The integrated supply chain production base located in Suzhou Industrial Park is a large comprehensive industrial park of Johnson & Johnson Medical Technology in China. It integrates the research and development and manufacturing of medical equipment, technological innovation and cooperation, global shared services, regional procurement and supplier management. and other diversified business functions, among which the intelligent manufacturing factory produces a series of innovative products such as surgery and orthopedics, responds to local demand and supplies globally. Johnson & Johnson Medical Technology not only focuses on cultivating and upgrading local intelligent manufacturing capabilities, but also further focuses on local R&D and innovation capabilities. In addition to Suzhou Supply Chain Base, Guangzhou Beixiu Biotechnology Co., Ltd., a wholly-owned subsidiary of Johnson & Johnson, is a biotechnology company specializing in technology development, research and production of pig-derived biological products. Beixiu independently developed the technology to extract fibrinogen and thrombin from mammalian blood, which is the world's first biomedical innovation. On the road to growing together with China's medical and healthcare industry, Johnson & Johnson Medical Technology has deepened the professional education and training of Chinese professional medical staff and is committed to becoming a trustworthy partner of Chinese medical staff. In line with the purpose of "exploring human technology and caring about human health", three Johnson & Johnson Medical Technology Professional Education Academic Centers located in Beijing, Shanghai and Boao Lecheng Medical Pilot Zone and the digital doctor training and education platform "Ling Yimai" provide professional knowledge, Training to adapt to China's medical service environment and innovative medical education forms will be promoted to the professional and systematic development of continuing medical education. In addition, Johnson & Johnson Medical Technology is also actively working with partners from all walks of life to promote innovation cooperation, accelerate the transformation of innovative results, and serve patients. As part of Johnson & Johnson's China Innovation Engine Strategy, Johnson & Johnson cooperates with local companies to leverage digital technologies such as artificial intelligence, surgical robots, and big data to assist doctors in more effective perioperative work and establish localized digital surgical solutions.
Weigao was founded in 1988. With the simple and kindness of improving the lives of the elderly and widowed, he set up a small workshop in the township welfare home. Currently committed to developing its main business medical devices and medicine, covering an area of more than 6 million square meters, it has 13 industrial groups and more than 100 subsidiaries, including 3 listed companies and 8 overseas companies, and is located in 10 provinces and cities in China. A manufacturing base is built with more than 30,000 employees. We have always taken improving national health and breaking foreign monopoly as our mission. We have now become a global supplier of comprehensive, safe, reliable and trustworthy overall solutions for medical systems. Create a systematic R&D platform to enhance core competitiveness through innovation and enrich product structure. 15 national and provincial innovation platforms have been built, including the National Certified Enterprise Technology Center, National Engineering Research Center, National Innovation Pilot Enterprise, Academician Workstation, Postdoctoral Workstation, Taishan Scholar Laboratory, etc., and many other institutions, including the Chinese Academy of Sciences, the Chinese Academy of Engineering, 301 Hospital, etc. Our unit has carried out industry-university-research cooperation and established cooperative relationships with more than 100 academicians. It has more than 1,700 patents, more than 1,000 medical devices and drugs, and more than 200,000 specifications. Committed to solving the "bottleneck" problem in foreign countries, overcome 21 technical barriers, achieve domestic substitution for more than 100 products, undertake more than 30 national key projects, win 4 national scientific and technological progress awards, 2 national technological invention awards, and national excellent industry 1 gold medal in design. Adhere to scientific management and improve the management system. It has a national technical standard innovation base and a national certification and testing center, and has 1 international standards formulated by enterprises in the industry and 2 international standards proposals, leading or participating in 11 national standards. Improve product quality with advanced manufacturing technology, introduce advanced domestic and foreign automated production equipment, establish management systems such as intelligent manufacturing (MES), AI visual inspection, quality BI data, etc., continuously improve management and control processes, and carry out digital transformation to continuously improve production and manufacturing capabilities and Management level. Improve industrial layout, lay out chains, strengthen chains, and extend chains. Establish an industrial layout of the coordinated development of three types of business formats to create a medical ecological chain. The medical industry has focused on creating product lines such as clinical nursing, orthopedics, blood purification, drug packaging, medical intervention, surgical robots, and medical engineering. It ranks among the top in the country in terms of product lines such as nursing, hemodialysis, pharmaceutical packaging materials, and blood technology. The sales network is spread all over the country and abroad, with more than 100 sales offices, and has created the "Jierui" and "Vigao" brands, and its products are sold to more than 100 countries or regions around the world.
Weigao Group Co., Ltd.
Weigao was founded in 1988. With the simple and kindness of improving the lives of the elderly and widowed, he set up a small workshop in the township welfare home. Currently committed to developing its main business medical devices and medicine, covering an area of more than 6 million square meters, it has 13 industrial groups and more than 100 subsidiaries, including 3 listed companies and 8 overseas companies, and is located in 10 provinces and cities in China. A manufacturing base is built with more than 30,000 employees. We have always taken improving national health and breaking foreign monopoly as our mission. We have now become a global supplier of comprehensive, safe, reliable and trustworthy overall solutions for medical systems. Create a systematic R&D platform to enhance core competitiveness through innovation and enrich product structure. 15 national and provincial innovation platforms have been built, including the National Certified Enterprise Technology Center, National Engineering Research Center, National Innovation Pilot Enterprise, Academician Workstation, Postdoctoral Workstation, Taishan Scholar Laboratory, etc., and many other institutions, including the Chinese Academy of Sciences, the Chinese Academy of Engineering, 301 Hospital, etc. Our unit has carried out industry-university-research cooperation and established cooperative relationships with more than 100 academicians. It has more than 1,700 patents, more than 1,000 medical devices and drugs, and more than 200,000 specifications. Committed to solving the "bottleneck" problem in foreign countries, overcome 21 technical barriers, achieve domestic substitution for more than 100 products, undertake more than 30 national key projects, win 4 national scientific and technological progress awards, 2 national technological invention awards, and national excellent industry 1 gold medal in design. Adhere to scientific management and improve the management system. It has a national technical standard innovation base and a national certification and testing center, and has 1 international standards formulated by enterprises in the industry and 2 international standards proposals, leading or participating in 11 national standards. Improve product quality with advanced manufacturing technology, introduce advanced domestic and foreign automated production equipment, establish management systems such as intelligent manufacturing (MES), AI visual inspection, quality BI data, etc., continuously improve management and control processes, and carry out digital transformation to continuously improve production and manufacturing capabilities and Management level. Improve industrial layout, lay out chains, strengthen chains, and extend chains. Establish an industrial layout of the coordinated development of three types of business formats to create a medical ecological chain. The medical industry has focused on creating product lines such as clinical nursing, orthopedics, blood purification, drug packaging, medical intervention, surgical robots, and medical engineering. It ranks among the top in the country in terms of product lines such as nursing, hemodialysis, pharmaceutical packaging materials, and blood technology. The sales network is spread all over the country and abroad, with more than 100 sales offices, and has created the "Jierui" and "Vigao" brands, and its products are sold to more than 100 countries or regions around the world.
Beijing Digital Precision Medical Technology Co., Ltd.
Beijing Digital Precision Medical Technology Co., Ltd. is a provider of medical equipment and medical information solutions. It focuses on the development of precision optical molecular imaging surgical robot equipment and provides a comprehensive range of surgical imaging navigation solutions. Its core technology was incubated in the Key Laboratory of the Institute of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, and is the crystallization of research accumulation of major projects in many countries. It has strong technical advantages in precision tumor surgery, minimally invasive treatment, early diagnosis, etc., and related methods He Technology won the second prize of the National Science and Technology Progress Award and the second prize of the National Science and Technology Invention Award. The US invention patents and national invention patents authorized by relevant technology have won the Gold Award at the International Invention Expo, the Gold Award at the Geneva International Invention Expo, and the Gold Award at the National Invention Expo. The company has now formed a series of optical molecular imaging robot products such as handheld, open, and endoptic. Using optical molecular imaging surgery robot equipment, it can accurately image tiny lesions intraoperatively, accurately locate tumor boundaries, and accurately navigate minimally invasive surgery on liver cancer, breast cancer, lung cancer, oral cancer, and gastric cancer. At present, clinical experiments have been achieved in many hospitals such as 301 Hospital and Peking University People's Hospital, and have achieved good results.
Beijing Digital Precision Medical Technology Co., Ltd.
Beijing Digital Precision Medical Technology Co., Ltd. is a provider of medical equipment and medical information solutions. It focuses on the development of precision optical molecular imaging surgical robot equipment and provides a comprehensive range of surgical imaging navigation solutions. Its core technology was incubated in the Key Laboratory of the Institute of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, and is the crystallization of research accumulation of major projects in many countries. It has strong technical advantages in precision tumor surgery, minimally invasive treatment, early diagnosis, etc., and related methods He Technology won the second prize of the National Science and Technology Progress Award and the second prize of the National Science and Technology Invention Award. The US invention patents and national invention patents authorized by relevant technology have won the Gold Award at the International Invention Expo, the Gold Award at the Geneva International Invention Expo, and the Gold Award at the National Invention Expo. The company has now formed a series of optical molecular imaging robot products such as handheld, open, and endoptic. Using optical molecular imaging surgery robot equipment, it can accurately image tiny lesions intraoperatively, accurately locate tumor boundaries, and accurately navigate minimally invasive surgery on liver cancer, breast cancer, lung cancer, oral cancer, and gastric cancer. At present, clinical experiments have been achieved in many hospitals such as 301 Hospital and Peking University People's Hospital, and have achieved good results.
Shenzhen Anke High-tech Co., Ltd.
Shenzhen Anke High-Tech Co., Ltd. was established in 1986 and is one of the leading large-scale medical imaging equipment providers in China. Anke specializes in the research, development, production, sales and technical services of large-scale medical imaging equipment and minimally invasive therapeutic equipment. Its main products include X-ray computer tomography system (CT), magnetic resonance imaging system (MRI), X-ray photography system ( XR), minimally invasive therapeutic equipment. Since its establishment, the company has the mission of developing national high-tech medical devices, committed to the research and development of key technologies in the field of large-scale medical imaging equipment and independent brand product innovation, and continues to promote the import substitution process of mid-to-high-end medical device products. Anke is one of the earliest domestic companies to independently develop large-scale medical imaging equipment and minimally invasive therapeutic equipment, and has deep technical accumulation. As a national high-tech enterprise and Guangdong Engineering Technology Research and Development Center, the company has undertaken national scientific research and industry with the goal of striving to achieve the industrialization, scale and efficiency of high-end medical imaging equipment in my country, and has undertaken the "Digital Diagnosis and Treatment Equipment R&D" project of the Ministry of Science and Technology and other national scientific research and industry with the goal of striving to achieve the industrialization, scale and efficiency of China's high-end medical imaging equipment. and actively participated in the drafting of a number of industry standards related to medical imaging equipment such as CT, vehicle-mounted CT, digital breast machines, etc., making positive contributions to promoting the development of the industry. Based on technology and product innovation, Anke has gradually built a multi-level three-dimensional marketing service network covering major provinces and cities across the country and facing medical institutions at all levels. Through various forms such as industry-university-research cooperation, window demonstration hospitals, etc. Cooperation, the company's products have been sold to 100 Grade A hospitals across the country and have been widely recognized. In addition, the company actively implements the "going overseas" strategy, focusing on the CIS, Latin America, Africa and other regions, and promoting the popularization of medical imaging equipment worldwide.
Shenzhen Anke High-tech Co., Ltd.
Shenzhen Anke High-Tech Co., Ltd. was established in 1986 and is one of the leading large-scale medical imaging equipment providers in China. Anke specializes in the research, development, production, sales and technical services of large-scale medical imaging equipment and minimally invasive therapeutic equipment. Its main products include X-ray computer tomography system (CT), magnetic resonance imaging system (MRI), X-ray photography system ( XR), minimally invasive therapeutic equipment. Since its establishment, the company has the mission of developing national high-tech medical devices, committed to the research and development of key technologies in the field of large-scale medical imaging equipment and independent brand product innovation, and continues to promote the import substitution process of mid-to-high-end medical device products. Anke is one of the earliest domestic companies to independently develop large-scale medical imaging equipment and minimally invasive therapeutic equipment, and has deep technical accumulation. As a national high-tech enterprise and Guangdong Engineering Technology Research and Development Center, the company has undertaken national scientific research and industry with the goal of striving to achieve the industrialization, scale and efficiency of high-end medical imaging equipment in my country, and has undertaken the "Digital Diagnosis and Treatment Equipment R&D" project of the Ministry of Science and Technology and other national scientific research and industry with the goal of striving to achieve the industrialization, scale and efficiency of China's high-end medical imaging equipment. and actively participated in the drafting of a number of industry standards related to medical imaging equipment such as CT, vehicle-mounted CT, digital breast machines, etc., making positive contributions to promoting the development of the industry. Based on technology and product innovation, Anke has gradually built a multi-level three-dimensional marketing service network covering major provinces and cities across the country and facing medical institutions at all levels. Through various forms such as industry-university-research cooperation, window demonstration hospitals, etc. Cooperation, the company's products have been sold to 100 Grade A hospitals across the country and have been widely recognized. In addition, the company actively implements the "going overseas" strategy, focusing on the CIS, Latin America, Africa and other regions, and promoting the popularization of medical imaging equipment worldwide.
Shanghai MicroPort Medical Robotics (Group) Co., Ltd.
Shanghai Microinvasive Medical Robot (Group) Co., Ltd. (02252.HK, hereinafter referred to as "Minvasive Robot") is a subsidiary of Microinvasive Medical Science Co., Ltd. (00853.HK, hereinafter referred to as Minimally Invasive), and started R&D in 2014 Mailscopic surgical robot (as an internal incubation project of Minimally Invasive Group), a company was established in China in 2015, and began corporate operations, and started the development of Honghu orthopedic surgical robot. On November 2, 2021, Minimally Invasive Robot was successfully listed on the main board of the Hong Kong Stock Exchange. It shoulders the mission of providing a full solution for robotic intelligent surgery that can extend and reshape life. It embarks on a new journey of medical technology innovation and shapes super intelligent. In the era of surgery, we will realize the original intention of "making no difficult surgery in the world".
Shanghai MicroPort Medical Robotics (Group) Co., Ltd.
Shanghai Microinvasive Medical Robot (Group) Co., Ltd. (02252.HK, hereinafter referred to as "Minvasive Robot") is a subsidiary of Microinvasive Medical Science Co., Ltd. (00853.HK, hereinafter referred to as Minimally Invasive), and started R&D in 2014 Mailscopic surgical robot (as an internal incubation project of Minimally Invasive Group), a company was established in China in 2015, and began corporate operations, and started the development of Honghu orthopedic surgical robot. On November 2, 2021, Minimally Invasive Robot was successfully listed on the main board of the Hong Kong Stock Exchange. It shoulders the mission of providing a full solution for robotic intelligent surgery that can extend and reshape life. It embarks on a new journey of medical technology innovation and shapes super intelligent. In the era of surgery, we will realize the original intention of "making no difficult surgery in the world".
Beijing Brightway Vision Technology Co., Ltd.
Beijing Bohui Weikang Technology Co., Ltd. was founded in 2010 and is a national high-tech enterprise specializing in the research and development, production and operation of surgical robots. The company now has two core brands: Ruimi️® Shenwai Surgery Robot and Ruiyi Bo️® Oral Surgery Robot. Its business covers 24 provinces and cities across the country, serves hundreds of hospitals, and has conducted over 10,000 clinical surgeries in total. The company undertakes more than 10 projects and projects such as national and Beijing R&D plans, and has more than 100 core technical intellectual property rights, including 41 invention patents. In 2018, I was approved as a registered certificate for the third category of medical device of the domestic neurosurgery robot. I have now approved a total of 4 surgical robot product registration certificates, spanning the fields of neurosurgery and oral. Related academic research has been published in core SCI journals such as Nature. . In 2019, with 9 leading hospitals including Xuanwu Hospital of Capital Medical University, Beijing Tiantan Hospital affiliated to Capital Medical University, and China-Japan Friendship Hospital, jointly undertake the application demonstration project of the Ministry of Industry and Information Technology and the Health Commission of the State Council on Neurosurgery Robots, and build a domestic neurosurgery robotics doctor. Enterprise innovation collaboration platform. In 2020, it completed a 430 million round of financing, with a total financing of more than 600 million yuan. In 2021, it was approved as the "Beijing Engineering Research Center for Medical Imaging Navigation and Positioning Surgery Robot". Bai Huiweikang adheres to the concept of independent innovation and will enhance the core competitiveness of the company through continuous technological innovation, deepen its efforts in the field of medical surgical robots, provide services and guarantees for human life and health, and assist the Healthy China strategy.
Beijing Brightway Vision Technology Co., Ltd.
Beijing Bohui Weikang Technology Co., Ltd. was founded in 2010 and is a national high-tech enterprise specializing in the research and development, production and operation of surgical robots. The company now has two core brands: Ruimi️® Shenwai Surgery Robot and Ruiyi Bo️® Oral Surgery Robot. Its business covers 24 provinces and cities across the country, serves hundreds of hospitals, and has conducted over 10,000 clinical surgeries in total. The company undertakes more than 10 projects and projects such as national and Beijing R&D plans, and has more than 100 core technical intellectual property rights, including 41 invention patents. In 2018, I was approved as a registered certificate for the third category of medical device of the domestic neurosurgery robot. I have now approved a total of 4 surgical robot product registration certificates, spanning the fields of neurosurgery and oral. Related academic research has been published in core SCI journals such as Nature. . In 2019, with 9 leading hospitals including Xuanwu Hospital of Capital Medical University, Beijing Tiantan Hospital affiliated to Capital Medical University, and China-Japan Friendship Hospital, jointly undertake the application demonstration project of the Ministry of Industry and Information Technology and the Health Commission of the State Council on Neurosurgery Robots, and build a domestic neurosurgery robotics doctor. Enterprise innovation collaboration platform. In 2020, it completed a 430 million round of financing, with a total financing of more than 600 million yuan. In 2021, it was approved as the "Beijing Engineering Research Center for Medical Imaging Navigation and Positioning Surgery Robot". Bai Huiweikang adheres to the concept of independent innovation and will enhance the core competitiveness of the company through continuous technological innovation, deepen its efforts in the field of medical surgical robots, provide services and guarantees for human life and health, and assist the Healthy China strategy.
Huake Precision (Beijing) Medical Equipment Co., Ltd.
Huake Precision (Beijing) Medical Equipment Co., Ltd. focuses on the research and development, production and technical services of intelligent innovative medical devices. It is a leading enterprise in my country's neurosurgery innovative medical devices, providing comprehensive technology and product solutions for the treatment of brain diseases; the company won the National High-tech The titles of enterprises, national specialized and innovative "little giant", national intellectual property advantage enterprise, and the winning unit of the Ministry of Industry and Information Technology's artificial intelligence industry innovation task. The company's 9 products independently developed have obtained the registration certificate of NMPA Class III medical device, and 4 products have been approved for national innovative medical devices. It has now formed the SR series of neurosurgery robots, micro-neurosurgery robots Q300 series, and neurosurgery navigation NS series. 5 major product lines including the intracranial electrode series, magnetic resonance guided laser ablation treatment system LS series, serving more than 200 medical institutions across the country. Intracranial electrodes and neurosurgical surgical robots are among the top domestic market share; the company's neurosurgical surgical robots It is certified by the U.S. Food and Drug Administration (FDA) and is a FDA-certified Chinese neurosurgery robot. Beijing Huake Hang Seng Medical Technology Co., Ltd., a wholly-owned subsidiary, is a global intracranial electrode manufacturer; Huake Hang Seng focuses on the research and development, production and technical services of medical electrodes in the field of neurosurgery, and is a high-tech enterprise that realizes the commercialization of intracranial EEG signal acquisition consumables; It has been approved for registration certificates for 4 Class III medical devices, and the annual production and sales of HKHS intracranial electrodes have reached tens of thousands. It is clinically used in more than 200 Class III hospitals across the country, at the forefront of the domestic market, and has achieved overall replacement of imported products. The company not only focuses on technological innovation, but also focuses on providing high-quality solutions to the medical industry to promote the improvement of medical diagnosis and treatment levels, thereby promoting the continuous progress of medical technology. Huake Precision works together with the medical industry to create the future of smart medical care.
Huake Precision (Beijing) Medical Equipment Co., Ltd.
Huake Precision (Beijing) Medical Equipment Co., Ltd. focuses on the research and development, production and technical services of intelligent innovative medical devices. It is a leading enterprise in my country's neurosurgery innovative medical devices, providing comprehensive technology and product solutions for the treatment of brain diseases; the company won the National High-tech The titles of enterprises, national specialized and innovative "little giant", national intellectual property advantage enterprise, and the winning unit of the Ministry of Industry and Information Technology's artificial intelligence industry innovation task. The company's 9 products independently developed have obtained the registration certificate of NMPA Class III medical device, and 4 products have been approved for national innovative medical devices. It has now formed the SR series of neurosurgery robots, micro-neurosurgery robots Q300 series, and neurosurgery navigation NS series. 5 major product lines including the intracranial electrode series, magnetic resonance guided laser ablation treatment system LS series, serving more than 200 medical institutions across the country. Intracranial electrodes and neurosurgical surgical robots are among the top domestic market share; the company's neurosurgical surgical robots It is certified by the U.S. Food and Drug Administration (FDA) and is a FDA-certified Chinese neurosurgery robot. Beijing Huake Hang Seng Medical Technology Co., Ltd., a wholly-owned subsidiary, is a global intracranial electrode manufacturer; Huake Hang Seng focuses on the research and development, production and technical services of medical electrodes in the field of neurosurgery, and is a high-tech enterprise that realizes the commercialization of intracranial EEG signal acquisition consumables; It has been approved for registration certificates for 4 Class III medical devices, and the annual production and sales of HKHS intracranial electrodes have reached tens of thousands. It is clinically used in more than 200 Class III hospitals across the country, at the forefront of the domestic market, and has achieved overall replacement of imported products. The company not only focuses on technological innovation, but also focuses on providing high-quality solutions to the medical industry to promote the improvement of medical diagnosis and treatment levels, thereby promoting the continuous progress of medical technology. Huake Precision works together with the medical industry to create the future of smart medical care.
Zimmer (Shanghai) Medical International Trading Co., Ltd.
ZimmerBiomet is one of the benchmark companies in the global medical technology field and has a comprehensive product portfolio. It aims to help improve health by maximizing patient mobility; further improve patient experience by leveraging innovative products of data, data analytics and artificial intelligence, and integrating digital and robotics. The company was founded in 1927 and is headquartered in Warsaw, Indiana, USA. It is a pioneer in the global orthopedic industry. It focuses on the design, research and development and production of joint prostheses, trauma systems, spine systems, dental implants and related orthopedic surgical products. With more than 90 years of industry experience and rich professional knowledge, relying on operating branches in more than 25 countries around the world and sales networks in more than 100 countries, ZimmerBiomet is determined to provide outstanding solutions for patients and medical institutions. . ZimmerBiomet is also one of the orthopedic companies that entered China earlier. It entered China in 1994 and established four regional offices in 2001. For more than ten years, Jiemai has been committed to continuing education for orthopedic doctors in China and has trained a large number of orthopedic doctors.
Zimmer (Shanghai) Medical International Trading Co., Ltd.
ZimmerBiomet is one of the benchmark companies in the global medical technology field and has a comprehensive product portfolio. It aims to help improve health by maximizing patient mobility; further improve patient experience by leveraging innovative products of data, data analytics and artificial intelligence, and integrating digital and robotics. The company was founded in 1927 and is headquartered in Warsaw, Indiana, USA. It is a pioneer in the global orthopedic industry. It focuses on the design, research and development and production of joint prostheses, trauma systems, spine systems, dental implants and related orthopedic surgical products. With more than 90 years of industry experience and rich professional knowledge, relying on operating branches in more than 25 countries around the world and sales networks in more than 100 countries, ZimmerBiomet is determined to provide outstanding solutions for patients and medical institutions. . ZimmerBiomet is also one of the orthopedic companies that entered China earlier. It entered China in 1994 and established four regional offices in 2001. For more than ten years, Jiemai has been committed to continuing education for orthopedic doctors in China and has trained a large number of orthopedic doctors.
Beijing Tianzhihang Medical Technology Co., Ltd.
Beijing Tianzhihang Medical Technology Co., Ltd. (stock code: 688277; hereinafter referred to as "Tianzhihang") is a high-tech company focusing on independent innovation, large-scale production, professional marketing and high-quality clinical applications of orthopedic surgical robots and their related technologies. Technology companies are also companies that have obtained medical robot registration licenses at home and abroad. In 2020, Tianzhihang Company successfully listed on the Science and Technology Innovation Board. As a pioneer of medical robots in China, Tianzhihang has obtained more than 300 patents. It is a member unit of the "National Robot Standardization Overall Group" and a supporting unit of the "National and Local Joint Engineering Research Center of Medical Robots"; it is a member unit of the China Medical Equipment Association and China Biology Deputy Chairman of the Medical Robot Engineering and Clinical Application Branch of the Society of Medical Engineering, a member of the TOP10 China Robot Summit, and an innovative leading enterprise of Beijing Biopharmaceutical Industry Leapfrog Development Project (G20 Project). It has won the second class of the 2015 National Science and Technology Progress Award Awards and other national and provincial and ministerial honors, and have a postdoctoral research workstation. The company's core product Dimensity orthopedic surgery robot has innovatively achieved a multi-indication coverage of one machine, including full-segment spinal surgery for the cervical spine, thoracic spine, lumbar spine, and sacral spine, as well as trauma surgery and joint replacement surgery in the pelvis, acetabular, limbs and other parts. As of the end of June 2024, the clinical application of Dimensity series orthopedic robots has covered more than 200 medical institutions, covering 31 provinces, autonomous regions, and municipalities, with the number of surgeries exceeding 80,000.
Beijing Tianzhihang Medical Technology Co., Ltd.
Beijing Tianzhihang Medical Technology Co., Ltd. (stock code: 688277; hereinafter referred to as "Tianzhihang") is a high-tech company focusing on independent innovation, large-scale production, professional marketing and high-quality clinical applications of orthopedic surgical robots and their related technologies. Technology companies are also companies that have obtained medical robot registration licenses at home and abroad. In 2020, Tianzhihang Company successfully listed on the Science and Technology Innovation Board. As a pioneer of medical robots in China, Tianzhihang has obtained more than 300 patents. It is a member unit of the "National Robot Standardization Overall Group" and a supporting unit of the "National and Local Joint Engineering Research Center of Medical Robots"; it is a member unit of the China Medical Equipment Association and China Biology Deputy Chairman of the Medical Robot Engineering and Clinical Application Branch of the Society of Medical Engineering, a member of the TOP10 China Robot Summit, and an innovative leading enterprise of Beijing Biopharmaceutical Industry Leapfrog Development Project (G20 Project). It has won the second class of the 2015 National Science and Technology Progress Award Awards and other national and provincial and ministerial honors, and have a postdoctoral research workstation. The company's core product Dimensity orthopedic surgery robot has innovatively achieved a multi-indication coverage of one machine, including full-segment spinal surgery for the cervical spine, thoracic spine, lumbar spine, and sacral spine, as well as trauma surgery and joint replacement surgery in the pelvis, acetabular, limbs and other parts. As of the end of June 2024, the clinical application of Dimensity series orthopedic robots has covered more than 200 medical institutions, covering 31 provinces, autonomous regions, and municipalities, with the number of surgeries exceeding 80,000.
Boyilai (Beijing) Medical Equipment Trading Co., Ltd.
Brainlab – Promote digital medical technology reform. For more than a quarter of a century, Brainlab has continuously promoted the development and innovation of hardware and software technologies in the fields of surgery and radiotherapy, supporting medical institutions, doctors and patients to fight cancer and other brain/body diseases. As a pioneer in digital health technology, Brainlab explores and identifies new opportunities to develop good treatments for patients. Brainlab is eager to help healthcare providers treat patients with severe medical conditions in a good way while improving the quality of life of patients. Thanks to innovative technology, Brainlab can remove brain tumors more safely, place screws more consistently in the spine, and can irradiate lung tumors more accurately. Overall, with Brainlab’s technology, surgical intervention has become more effective, more targeted and safer. Curiosity drives Brainlab to integrate medical data with innovative technologies to benefit patients. Brainlab’s software summarizes and correlates patient data into an anatomical digital patient model that continuously improves and improves using artificial intelligence and precision algorithms. By converging the digital and physical worlds, Brainlab can provide and process critical personalized patient information when needed. Brainlab is committed to developing comprehensive surgical operating systems with open interfaces and standardized formats. Therefore, Brainlab is happy to share know-how. To benefit as many patients as possible from Brainlab’s solutions, Brainlab provides data and underlying technology to other companies in the digital ecosystem. In this way, Brainlab combines knowledge from various clinical fields and plays a synergistic role. Brainlab’s goal is to support all patients with better treatment outcomes by introducing innovative digital technologies to support all those involved in combating life-threatening diseases and medical conditions.
Boyilai (Beijing) Medical Equipment Trading Co., Ltd.
Brainlab – Promote digital medical technology reform. For more than a quarter of a century, Brainlab has continuously promoted the development and innovation of hardware and software technologies in the fields of surgery and radiotherapy, supporting medical institutions, doctors and patients to fight cancer and other brain/body diseases. As a pioneer in digital health technology, Brainlab explores and identifies new opportunities to develop good treatments for patients. Brainlab is eager to help healthcare providers treat patients with severe medical conditions in a good way while improving the quality of life of patients. Thanks to innovative technology, Brainlab can remove brain tumors more safely, place screws more consistently in the spine, and can irradiate lung tumors more accurately. Overall, with Brainlab’s technology, surgical intervention has become more effective, more targeted and safer. Curiosity drives Brainlab to integrate medical data with innovative technologies to benefit patients. Brainlab’s software summarizes and correlates patient data into an anatomical digital patient model that continuously improves and improves using artificial intelligence and precision algorithms. By converging the digital and physical worlds, Brainlab can provide and process critical personalized patient information when needed. Brainlab is committed to developing comprehensive surgical operating systems with open interfaces and standardized formats. Therefore, Brainlab is happy to share know-how. To benefit as many patients as possible from Brainlab’s solutions, Brainlab provides data and underlying technology to other companies in the digital ecosystem. In this way, Brainlab combines knowledge from various clinical fields and plays a synergistic role. Brainlab’s goal is to support all patients with better treatment outcomes by introducing innovative digital technologies to support all those involved in combating life-threatening diseases and medical conditions.
Harbin Sichuangrui Intelligent Medical Equipment Co., Ltd.
Harbin Sizherui Intelligent Medical Equipment Co., Ltd. is a high-tech enterprise focusing on the research, development, production and sales of surgical robots. It is committed to creating intelligent surgical tools for doctors and providing patients with comprehensive diagnosis and treatment plans, making various surgical procedures more convenient. Since its establishment, the company has always insisted on independent innovation and strived to break the monopoly of foreign products. After nearly ten years of exploration and accumulation, it has formed a series of core technologies and original results in the field of surgical robots, and has developed and built laparoscopic surgical robots and transurethral flexibility. There are rich surgical robot product matrix such as surgical robots, transoral surgical robots, cochlear implant surgical robots, spinal endoscopic surgical robots, etc., suitable for urology, gynecology, general surgery, thoracic surgery, otolaryngology, head and neck surgery, orthopedics and other departments. The company's core product, Condo Robot®, is a laparoscopic surgical robot that has entered the national special approval procedure for innovative medical devices (green channel) in the field of urology. It has obtained the third-class medical device registration certificate in June 2022. Condo Robot® is also a domestic laparoscopic surgical robot that has performed operations in a single hospital to reach 100. The company insists on independent research and development and technological innovation, and has a number of core technologies such as surgical robot creation technology, surgical robot arm technology, main operating hand technology, surgical instrument technology, main slave remote operation technology, and surgical navigation technology. Up to now, the company has obtained 160 patent authorizations, including 42 invention patents, and has built an independent and complete intellectual property system. The company's products have strong academic influence. Many academic papers on Condo Robot® have been published in domestic and foreign journals such as the Chinese Journal of Urology and the British Journal of Urology, especially in July 2022 as published. Research on domestic laparoscopic surgical robot systems in the official journal of the American Urological Association (AUA) represents the Western academic community dominated by the American Da Vinci surgical robot system for Chinese domestic surgical robots Highly recognized for the clinical application of the system.
Harbin Sichuangrui Intelligent Medical Equipment Co., Ltd.
Harbin Sizherui Intelligent Medical Equipment Co., Ltd. is a high-tech enterprise focusing on the research, development, production and sales of surgical robots. It is committed to creating intelligent surgical tools for doctors and providing patients with comprehensive diagnosis and treatment plans, making various surgical procedures more convenient. Since its establishment, the company has always insisted on independent innovation and strived to break the monopoly of foreign products. After nearly ten years of exploration and accumulation, it has formed a series of core technologies and original results in the field of surgical robots, and has developed and built laparoscopic surgical robots and transurethral flexibility. There are rich surgical robot product matrix such as surgical robots, transoral surgical robots, cochlear implant surgical robots, spinal endoscopic surgical robots, etc., suitable for urology, gynecology, general surgery, thoracic surgery, otolaryngology, head and neck surgery, orthopedics and other departments. The company's core product, Condo Robot®, is a laparoscopic surgical robot that has entered the national special approval procedure for innovative medical devices (green channel) in the field of urology. It has obtained the third-class medical device registration certificate in June 2022. Condo Robot® is also a domestic laparoscopic surgical robot that has performed operations in a single hospital to reach 100. The company insists on independent research and development and technological innovation, and has a number of core technologies such as surgical robot creation technology, surgical robot arm technology, main operating hand technology, surgical instrument technology, main slave remote operation technology, and surgical navigation technology. Up to now, the company has obtained 160 patent authorizations, including 42 invention patents, and has built an independent and complete intellectual property system. The company's products have strong academic influence. Many academic papers on Condo Robot® have been published in domestic and foreign journals such as the Chinese Journal of Urology and the British Journal of Urology, especially in July 2022 as published. Research on domestic laparoscopic surgical robot systems in the official journal of the American Urological Association (AUA) represents the Western academic community dominated by the American Da Vinci surgical robot system for Chinese domestic surgical robots Highly recognized for the clinical application of the system.
Virtual Incision Corporation
Virtual Incision develops miniaturized robotic surgical systems for minimally invasive procedures, focusing on portability and accessibility.
Virtual Incision Corporation
Virtual Incision develops miniaturized robotic surgical systems for minimally invasive procedures, focusing on portability and accessibility.
Senhance is a digital laparoscopic platform that offers haptic feedback and 3D visualization for enhanced surgical precision.
Asensus Surgical
Senhance is a digital laparoscopic platform that offers haptic feedback and 3D visualization for enhanced surgical precision.
Hugo RAS is a modular robotic-assisted surgery system aimed at providing a cost-effective and versatile solution for minimally invasive procedures.
Medtronic
Hugo RAS is a modular robotic-assisted surgery system aimed at providing a cost-effective and versatile solution for minimally invasive procedures.
Versius is a modular and portable surgical robot designed to perform minimally invasive surgeries with precision and flexibility.
CMR Surgical
Versius is a modular and portable surgical robot designed to perform minimally invasive surgeries with precision and flexibility.
An American brand known for its artist-grade oil paints and mediums, offering a wide range of colors and formulations.
Da Vinci Paint Co.
An American brand known for its artist-grade oil paints and mediums, offering a wide range of colors and formulations.
Ningbo Supertop Electrical Appliance Co., Ltd.
Ningbo SBOT Electrical Appliances Co., Ltd. is located in Cixi, Zhejiang, China's small home appliance production base. The company has an elegant geographical environment, 75 kilometers away from Beilun Port in the east, 60 kilometers away from Ningbo Lishe Airport, 40 kilometers away from the Hangzhou-Ningbo Expressway in the west, Rely on National Highway 329. The company mainly produces various types of heaters, water dispensers, electric fans, electric oil swelling, infant and toddler milking machines and other products of hundreds of specifications. The products are best sold all over the country and have dealer agents in large and medium-sized cities. With the growth of technological strength and the increase in production capacity, products have gradually entered the international market and participated in the competition in the foreign home appliance market.
Ningbo Supertop Electrical Appliance Co., Ltd.
Ningbo SBOT Electrical Appliances Co., Ltd. is located in Cixi, Zhejiang, China's small home appliance production base. The company has an elegant geographical environment, 75 kilometers away from Beilun Port in the east, 60 kilometers away from Ningbo Lishe Airport, 40 kilometers away from the Hangzhou-Ningbo Expressway in the west, Rely on National Highway 329. The company mainly produces various types of heaters, water dispensers, electric fans, electric oil swelling, infant and toddler milking machines and other products of hundreds of specifications. The products are best sold all over the country and have dealer agents in large and medium-sized cities. With the growth of technological strength and the increase in production capacity, products have gradually entered the international market and participated in the competition in the foreign home appliance market.
